Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937092 | 0.86 | RORC (0.44) | RORCUSP30GPR119NAMPTJAK2 | |
| SCHEMBL31245750 | 0.86 | RORC (0.44) | RORCUSP30GPR119NAMPTJAK2 | |
| SCHEMBL29937470 | 0.86 | RORC (0.44) | RORCUSP30GPR119NAMPTJAK2 | |
| SCHEMBL29344016 | 0.86 | RORC (0.49) | RORCUSP30GPR119NAMPTJAK2 | |
| SCHEMBL31245749 | 0.86 | RORC (0.49) | RORCUSP30GPR119NAMPTJAK2 | |
| SCHEMBL24894326 | 0.86 | RORC (0.44) | RORCUSP30GPR119NAMPTJAK2 | |
| SCHEMBL30998669 | 0.83 | JAK1 (0.45) | RORCUSP30GPR119NAMPTJAK2 | |
| SCHEMBL30998555 | 0.83 | JAK1 (0.45) | RORCUSP30GPR119NAMPTJAK2 | |
| SCHEMBL24894678 | 0.83 | JAK1 (0.45) | RORCUSP30GPR119NAMPTJAK2 | |
| SCHEMBL29827622 | 0.83 | JAK1 (0.45) | RORCUSP30GPR119NAMPTJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | RORC 2746/4885USP30 1031/4885GPR119 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.